Review



ihc staining for pdk4 expression  (Biomax Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Biomax Inc ihc staining for pdk4 expression
    Ihc Staining For Pdk4 Expression, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+staining+for+pdk4+expression/ihc+staining+for+pdk4+expression/pm32390009-119-517-466
    Average 90 stars, based on 1 article reviews
    ihc staining for pdk4 expression - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
    Article Snippet: Since cell death could affect the effects of PDK4 as presented above, we further evaluated the cell Normal ovary or benign tumours (n =5) Malignant tumours (n =97) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) ** Stage 1 Stage 2 Stage 3 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =53) (n =19) (n =25) ** ** ** Serous Mucinous Endometrioid Clear cell 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =18)(n =50) (n =28) ** ** n.s. (n =2) 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 413 97 10 2Low 144 23 2 0High HR = 1.48 (1.14–1.91) Log-rank P = 0.0029 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 386 38 2 1Low 136 3 0 0High HR = 1.47 (1.13–1.91) Log-rank P = 0.0036 Primary tumour Metastatic foci 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =16) (n =16) ** a c b d Grade I–II Grade II–III 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =31) (n =66) n.s. i ii iii iv v i Primary ovarian tumours Matched metastatic tumours ii iii iv HO SE 9 6- 9- 18 SK OV 3 OV CA R3 OV CA 42 0 TO V1 12 D OV TO KO 0 20 40 60 ** ** ** ** ** R el at iv e m R N A e xp re ss io n of P D K 4 e Fig. 3 PDK4 is overexpressed in ovarian cancer and correlates with metastasis and poor prognosis. a Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in (i) normal ovarian tissue, (ii) serous, (iii) mucinous, (iv) endometrioid and (v) clear cell subtypes of tumour samples on ovarian cancer TMA (OVC1021, Biomax). b Correlation of PDK4 with clinicopathologic parameters in ovarian cancer. c (Left) Overall and (right) progression-free survival rates were analysed with the log-rank test for PDKhigh/low groups of ovarian cancer patients obtained from TGCA using the Kaplan–Meier plotter. d (Left) Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in ovarian primary and matched metastatic tumours. (Right) Dot plot showing PDK4 positivity in primary and metastatic ovarian tumours. e PDK4 mRNA expression in normal human ovarian surface epithelial cell line (HOSE) and ovarian cancer cell lines as determined by qPCR (*p < 0.05, **p < 0.01; n.s., not significant). viability of tumourspheres and ALDH+CD44+ cells after PDK4 knockdown.

    Immunohistochemistry:

    Article Title: Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
    Article Snippet: Since cell death could affect the effects of PDK4 as presented above, we further evaluated the cell Normal ovary or benign tumours (n =5) Malignant tumours (n =97) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) ** Stage 1 Stage 2 Stage 3 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =53) (n =19) (n =25) ** ** ** Serous Mucinous Endometrioid Clear cell 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =18)(n =50) (n =28) ** ** n.s. (n =2) 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 413 97 10 2Low 144 23 2 0High HR = 1.48 (1.14–1.91) Log-rank P = 0.0029 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 386 38 2 1Low 136 3 0 0High HR = 1.47 (1.13–1.91) Log-rank P = 0.0036 Primary tumour Metastatic foci 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =16) (n =16) ** a c b d Grade I–II Grade II–III 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =31) (n =66) n.s. i ii iii iv v i Primary ovarian tumours Matched metastatic tumours ii iii iv HO SE 9 6- 9- 18 SK OV 3 OV CA R3 OV CA 42 0 TO V1 12 D OV TO KO 0 20 40 60 ** ** ** ** ** R el at iv e m R N A e xp re ss io n of P D K 4 e Fig. 3 PDK4 is overexpressed in ovarian cancer and correlates with metastasis and poor prognosis. a Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in (i) normal ovarian tissue, (ii) serous, (iii) mucinous, (iv) endometrioid and (v) clear cell subtypes of tumour samples on ovarian cancer TMA (OVC1021, Biomax). b Correlation of PDK4 with clinicopathologic parameters in ovarian cancer. c (Left) Overall and (right) progression-free survival rates were analysed with the log-rank test for PDKhigh/low groups of ovarian cancer patients obtained from TGCA using the Kaplan–Meier plotter. d (Left) Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in ovarian primary and matched metastatic tumours. (Right) Dot plot showing PDK4 positivity in primary and metastatic ovarian tumours. e PDK4 mRNA expression in normal human ovarian surface epithelial cell line (HOSE) and ovarian cancer cell lines as determined by qPCR (*p < 0.05, **p < 0.01; n.s., not significant). viability of tumourspheres and ALDH+CD44+ cells after PDK4 knockdown.

    Staining:

    Article Title: Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
    Article Snippet: Since cell death could affect the effects of PDK4 as presented above, we further evaluated the cell Normal ovary or benign tumours (n =5) Malignant tumours (n =97) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) ** Stage 1 Stage 2 Stage 3 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =53) (n =19) (n =25) ** ** ** Serous Mucinous Endometrioid Clear cell 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =18)(n =50) (n =28) ** ** n.s. (n =2) 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 413 97 10 2Low 144 23 2 0High HR = 1.48 (1.14–1.91) Log-rank P = 0.0029 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 386 38 2 1Low 136 3 0 0High HR = 1.47 (1.13–1.91) Log-rank P = 0.0036 Primary tumour Metastatic foci 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =16) (n =16) ** a c b d Grade I–II Grade II–III 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =31) (n =66) n.s. i ii iii iv v i Primary ovarian tumours Matched metastatic tumours ii iii iv HO SE 9 6- 9- 18 SK OV 3 OV CA R3 OV CA 42 0 TO V1 12 D OV TO KO 0 20 40 60 ** ** ** ** ** R el at iv e m R N A e xp re ss io n of P D K 4 e Fig. 3 PDK4 is overexpressed in ovarian cancer and correlates with metastasis and poor prognosis. a Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in (i) normal ovarian tissue, (ii) serous, (iii) mucinous, (iv) endometrioid and (v) clear cell subtypes of tumour samples on ovarian cancer TMA (OVC1021, Biomax). b Correlation of PDK4 with clinicopathologic parameters in ovarian cancer. c (Left) Overall and (right) progression-free survival rates were analysed with the log-rank test for PDKhigh/low groups of ovarian cancer patients obtained from TGCA using the Kaplan–Meier plotter. d (Left) Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in ovarian primary and matched metastatic tumours. (Right) Dot plot showing PDK4 positivity in primary and metastatic ovarian tumours. e PDK4 mRNA expression in normal human ovarian surface epithelial cell line (HOSE) and ovarian cancer cell lines as determined by qPCR (*p < 0.05, **p < 0.01; n.s., not significant). viability of tumourspheres and ALDH+CD44+ cells after PDK4 knockdown.

    Real-time Polymerase Chain Reaction:

    Article Title: Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
    Article Snippet: Since cell death could affect the effects of PDK4 as presented above, we further evaluated the cell Normal ovary or benign tumours (n =5) Malignant tumours (n =97) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) ** Stage 1 Stage 2 Stage 3 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =53) (n =19) (n =25) ** ** ** Serous Mucinous Endometrioid Clear cell 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =18)(n =50) (n =28) ** ** n.s. (n =2) 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 413 97 10 2Low 144 23 2 0High HR = 1.48 (1.14–1.91) Log-rank P = 0.0029 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 386 38 2 1Low 136 3 0 0High HR = 1.47 (1.13–1.91) Log-rank P = 0.0036 Primary tumour Metastatic foci 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =16) (n =16) ** a c b d Grade I–II Grade II–III 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =31) (n =66) n.s. i ii iii iv v i Primary ovarian tumours Matched metastatic tumours ii iii iv HO SE 9 6- 9- 18 SK OV 3 OV CA R3 OV CA 42 0 TO V1 12 D OV TO KO 0 20 40 60 ** ** ** ** ** R el at iv e m R N A e xp re ss io n of P D K 4 e Fig. 3 PDK4 is overexpressed in ovarian cancer and correlates with metastasis and poor prognosis. a Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in (i) normal ovarian tissue, (ii) serous, (iii) mucinous, (iv) endometrioid and (v) clear cell subtypes of tumour samples on ovarian cancer TMA (OVC1021, Biomax). b Correlation of PDK4 with clinicopathologic parameters in ovarian cancer. c (Left) Overall and (right) progression-free survival rates were analysed with the log-rank test for PDKhigh/low groups of ovarian cancer patients obtained from TGCA using the Kaplan–Meier plotter. d (Left) Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in ovarian primary and matched metastatic tumours. (Right) Dot plot showing PDK4 positivity in primary and metastatic ovarian tumours. e PDK4 mRNA expression in normal human ovarian surface epithelial cell line (HOSE) and ovarian cancer cell lines as determined by qPCR (*p < 0.05, **p < 0.01; n.s., not significant). viability of tumourspheres and ALDH+CD44+ cells after PDK4 knockdown.

    Knockdown:

    Article Title: Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
    Article Snippet: Since cell death could affect the effects of PDK4 as presented above, we further evaluated the cell Normal ovary or benign tumours (n =5) Malignant tumours (n =97) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) ** Stage 1 Stage 2 Stage 3 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =53) (n =19) (n =25) ** ** ** Serous Mucinous Endometrioid Clear cell 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =18)(n =50) (n =28) ** ** n.s. (n =2) 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 413 97 10 2Low 144 23 2 0High HR = 1.48 (1.14–1.91) Log-rank P = 0.0029 0 50 100 150 0.0 0.2 0.4 0.6 0.8 1.0 Time (months) P ro ba bi lit y Expression Low High Number at risk 386 38 2 1Low 136 3 0 0High HR = 1.47 (1.13–1.91) Log-rank P = 0.0036 Primary tumour Metastatic foci 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =16) (n =16) ** a c b d Grade I–II Grade II–III 0.0 0.2 0.4 0.6 0.8 1.0 1.2 P os iti vi ty (n um be r of p os iti ve p ix el s/ T ot al n um be r of p ix el s) (n =31) (n =66) n.s. i ii iii iv v i Primary ovarian tumours Matched metastatic tumours ii iii iv HO SE 9 6- 9- 18 SK OV 3 OV CA R3 OV CA 42 0 TO V1 12 D OV TO KO 0 20 40 60 ** ** ** ** ** R el at iv e m R N A e xp re ss io n of P D K 4 e Fig. 3 PDK4 is overexpressed in ovarian cancer and correlates with metastasis and poor prognosis. a Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in (i) normal ovarian tissue, (ii) serous, (iii) mucinous, (iv) endometrioid and (v) clear cell subtypes of tumour samples on ovarian cancer TMA (OVC1021, Biomax). b Correlation of PDK4 with clinicopathologic parameters in ovarian cancer. c (Left) Overall and (right) progression-free survival rates were analysed with the log-rank test for PDKhigh/low groups of ovarian cancer patients obtained from TGCA using the Kaplan–Meier plotter. d (Left) Representative images (scale bar, 100 μΜ) of IHC staining for PDK4 expression in ovarian primary and matched metastatic tumours. (Right) Dot plot showing PDK4 positivity in primary and metastatic ovarian tumours. e PDK4 mRNA expression in normal human ovarian surface epithelial cell line (HOSE) and ovarian cancer cell lines as determined by qPCR (*p < 0.05, **p < 0.01; n.s., not significant). viability of tumourspheres and ALDH+CD44+ cells after PDK4 knockdown.



    Similar Products

    ihc staining for pdk4 expression  (Biomax Inc)
    90
    Biomax Inc ihc staining for pdk4 expression
    Ihc Staining For Pdk4 Expression, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+staining+for+pdk4+expression/ihc+staining+for+pdk4+expression/pm32390009-119-517-466
    Average 90 stars, based on 1 article reviews
    ihc staining for pdk4 expression - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results